Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy
Although immune checkpoint blockade (ICB) therapies have achieved great progress, the patient response varies among cancers. In this study, we analyzed the potential genomic indicators contributing to ICB therapy response. The results showed that high tumor mutation burden (TMB) failed to predict re...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2022-09-01
|
| シリーズ: | Cells |
| 主題: | |
| オンライン･アクセス: | https://www.mdpi.com/2073-4409/11/18/2802 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|